Fig. 7: ABHD11 inhibition delays the onset of type 1 diabetes.
From: Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function
a Schematic overview of in vivo diabetes adoptive transfer model using BDC2.5 HIP-activated BDC2.5 CD4+ T-cells. b Diabetes incidence, as confirmed by blood glucose measurement >13.9 mmol/L, in the presence and absence of daily injections i.p of 2.5 mg/kg WWL222 (n = 10). c Surface expression of CD69, as a measure of activation, on CD4+ T-cells (n = 5). d Intracellular TNFα and IL-2 expression in CD4+ T-cells (n = 5). e Schematic overview of in vivo diabetes adoptive transfer model using splenocytes. f Diabetes incidence, as confirmed by blood glucose measurement >13.9 mmol/L, in the presence and absence of daily injections i.p of 2.5 mg/kg WWL222 (n = 6). g Intracellular IFNγ expression in CD4+ T-cells (n = 3). All experiments were carried out using murine samples. Mice were injected daily with the indicated dose of WWL222. Data are expressed as median ± interquartile range. Statistical tests used: log-rank (Mantel–Cox) test (b, f), two-tailed unpaired t-test (c, d, g). Source data are provided as a Source Data file.
